Univariable and multivariable binary logistic regression analysis of rehospitalization during the first year.
| Variables | Univariable Analysis | Multivariable Analysis1 | ||
|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) | p | |
| Age (per yr) | 0.99 (0.91–1.09) | 0.89 | 0.99 (0.89–1.10) | 0.82 |
| Male sex | 0.73 (0.37–1.41) | 0.34 | 0.50 (0.24–1.06) | 0.072 |
| BVAS (per point)2 | 1.05 (0.98–1.11) | 0.16 | 1.02 (0.95–1.10) | 0.63 |
| MPO/pANCA | 0.56 (0.27–1.16) | 0.12 | 0.36 (0.15–0.87) | 0.024 |
| CRP (per percentile)3 | 1.02 (0.82–1.26) | 0.89 | 1.02 (0.78–1.34) | 0.87 |
| Creatinine (per percentile)4 | 1.22 (0.98–1.52) | 0.072 | 1.34 (1.02–1.78) | 0.039 |
| Comorbidity score (per point) | 1.18 (0.78–1.80) | 0.43 | 1.23 (0.77–1.96) | 0.39 |
| CYC/RTX | 1.83 (0.82–4.09) | 0.14 | 2.21 (0.82–5.94) | 0.12 |
| Prednisolone dose (per percentile) | 1.05 (0.86–1.29) | 0.62 | 0.99 (0.76–1.30) | 0.96 |
| Methylprednisolone dose (per 250 mg) | 1.07 (0.93–1.23) | 0.37 | 1.02 (0.86–1.20) | 0.85 |
Analysis of 165 patients with complete treatment data and data on rehospitalization. CYC/RTX ≥ 2000 mg oral CYC/≥ 1500 mg intravenous CYC or RTX.
↵1 Multivariable analysis performed on 148 patients.
↵2 Data missing in 5 patients.
↵3 Data missing in 5 patients
↵4 Data missing in 7 patients. BVAS: Birmingham Vasculitis Activity Score; MPO: myeloperoxidase; pANCA: perinuclear antineutrophil cytoplasmic antibodies; CRP: C-reactive protein; CYC: cyclophosphamide; RTX: rituximab.